Stock Target in Focus for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Wall Street analysts that cover the company have offered target price estimates on the stock. The current consensus target price is $188.1 on shares. 10 analysts have been used for this consensus number which is provided by Zacks Research. Currently, the highest target estimate from covering analysts is $332. The lowest projection sees the stock heading to $60.  

Zacks research also gives calculated recommendations from sell-side analysts that cover company shares. These recommendations land on a simplified scale provided by Zacks Research. Using data provided from various analysts, shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) are presently listed with an ABR of 2.1. This number is using a recommendation scale where the ratings range from a 1 to a 5. Following this scale, a 1 would signify a Strong Buy while a 5 would represent a Strong Sell.

We can also take a look at some company earnings per share or EPS information. Earnings per share is the segment of profit for a company that is allocated to every outstanding share of a company’s common stock. Earnings per share numbers can serve as an indicator for the profitability of a certain company. EPS is broadly thought to be one of the most important factors when evaluating the price of a share. A Zacks consensus currently shows Street analysts projecting the company to post per share earnings of $-3.73. For the period ending 2016-06-30, Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) reported actual EPS of $-3.14. This number was $0.62 away from analyst predictions, providing a surprise factor of 16.49%. The company is expected to next release earnings on or around 2016-11-14.

The data in this report is in part provided by Zacks Research and Yahoo Finance.  The author does not have, nor plans to take any position in Intercept Pharmaceuticals, Inc. shares within the next 14 days.  Readers should not consider this as a recommendation to buy or sell company stock.  This piece is for informational purposes only.  Potentialy investors should always conduct full research before making investment decisions. 

Leave a Comment